Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study

Key Points

• Flumonertinib monotherapy may enhance survival outcomes for patients with EGFR-mutated non-small cell lung cancer.
• Survivors receiving flumonertinib earlier show promising improvements compared to delayed initiation of therapy.
• Observational analysis across various settings indicates significant benefits in rechallenge scenarios with flumonertinib.
• This study highlights the need for further research on optimal timing for initiating flumonertinib treatment.

Abstract